1. Home
  2. NPKI vs ORIC Comparison

NPKI vs ORIC Comparison

Compare NPKI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NPKI
  • ORIC
  • Stock Information
  • Founded
  • NPKI 1932
  • ORIC 2014
  • Country
  • NPKI United States
  • ORIC United States
  • Employees
  • NPKI N/A
  • ORIC N/A
  • Industry
  • NPKI Metal Fabrications
  • ORIC Biotechnology: Pharmaceutical Preparations
  • Sector
  • NPKI Industrials
  • ORIC Health Care
  • Exchange
  • NPKI Nasdaq
  • ORIC Nasdaq
  • Market Cap
  • NPKI 634.0M
  • ORIC 633.7M
  • IPO Year
  • NPKI N/A
  • ORIC 2020
  • Fundamental
  • Price
  • NPKI N/A
  • ORIC $8.21
  • Analyst Decision
  • NPKI
  • ORIC Strong Buy
  • Analyst Count
  • NPKI 0
  • ORIC 9
  • Target Price
  • NPKI N/A
  • ORIC $18.75
  • AVG Volume (30 Days)
  • NPKI 753.7K
  • ORIC 331.7K
  • Earning Date
  • NPKI 02-20-2025
  • ORIC 11-12-2024
  • Dividend Yield
  • NPKI N/A
  • ORIC N/A
  • EPS Growth
  • NPKI N/A
  • ORIC N/A
  • EPS
  • NPKI N/A
  • ORIC N/A
  • Revenue
  • NPKI $748,372,000.00
  • ORIC N/A
  • Revenue This Year
  • NPKI N/A
  • ORIC N/A
  • Revenue Next Year
  • NPKI N/A
  • ORIC N/A
  • P/E Ratio
  • NPKI $18.93
  • ORIC N/A
  • Revenue Growth
  • NPKI 93.70
  • ORIC N/A
  • 52 Week Low
  • NPKI $5.61
  • ORIC $6.33
  • 52 Week High
  • NPKI $8.65
  • ORIC $16.65
  • Technical
  • Relative Strength Index (RSI)
  • NPKI N/A
  • ORIC 40.22
  • Support Level
  • NPKI N/A
  • ORIC $7.41
  • Resistance Level
  • NPKI N/A
  • ORIC $8.42
  • Average True Range (ATR)
  • NPKI 0.00
  • ORIC 0.56
  • MACD
  • NPKI 0.00
  • ORIC -0.16
  • Stochastic Oscillator
  • NPKI 0.00
  • ORIC 28.57

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Share on Social Networks: